MedTrace Logo

Genomics and Efficacy of Post-prostatectomy Salvage Radiotherapy With 'Extreme' Hypofractionation

NCT06894628 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 103

Last updated 2025-03-25

No results posted yet for this study

Summary

The study aims to validate the Decipher® genomic test, in which patients with biochemical recurrence after radical prostatectomy are treated with salvage radiotherapy with extreme hypofractionation (5+ Gy/fraction).

Validating the Decipher® genomic classifier based on the expression of 22 RNA genes in the prospective study "esSBRT"

Conditions

  • Prostatic Neoplasms

Sponsors & Collaborators

  • Regina Elena Cancer Institute

    lead OTHER

Principal Investigators

  • Giuseppe Sanguineti, Doctor · IRCCS National Cancer Institute

Eligibility

Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-11-04
Primary Completion
2027-11-04
Completion
2027-11-04

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06894628 on ClinicalTrials.gov